Premium
Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients
Author(s) -
Hoffmann V.,
Kuhn W.,
Schimrigk S.,
Islamova S.,
Hellwig K.,
Lukas C.,
Brune N.,
Pöhlau D.,
Przuntek H.,
Müller T.
Publication year - 2006
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2006.01145.x
Subject(s) - medicine , triamcinolone acetonide , multiple sclerosis , cerebrospinal fluid , intrathecal , enolase , expanded disability status scale , anesthesia , gastroenterology , urology , surgery , immunology , immunohistochemistry
Available immunomodulatory and conventional steroid treatment regimens provide a limited symptomatic benefit for patients with progressive multiple sclerosis (MS). We performed an open trial on the short‐term efficacy of repeated intrathecal application of the sustained release steroid triamcinolone acetonide (TCA) in 27 progressive MS patients. Six TCA administrations, performed every third day, reduced the Expanded Disability Status Scale (EDSS) score [initial: 5.4 ± 1.3, 3–7.5 (mean ± SD, range); end: 4.9 ± 1.1; 2.5–6.5; P < 0.001] and significantly increased the walking distance and speed in particular after the fourth TCA injection. Concomitantly serially determined cerebrospinal fluid (CSF) markers of cell injury, neuron‐specific enolase, total τ ‐protein, S‐100, and β ‐amyloid did not significantly change within the interval of TCA treatment. No serious side effects appeared. We conclude that repeat intrathecal injection of 40 mg TCA provides a substantial benefit in progressive MS patients with predominant spinal symptoms and does not alter CSF markers of neuronal cell injury.